AI assistant
Aprea Therapeutics, Inc. — Director's Dealing 2024
Mar 15, 2024
35269_dirs_2024-03-14_f27c0f6a-15ff-4d74-af71-e33b6b9b3519.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2024-03-13
Reporting Person: Gilad Oren (Director, President, CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-13 | Common Stock | P | 2000 | $7.29 | Acquired | 324770 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-13 | Tranche A Warrant | $ | P | 1000 | Acquired | Common Stock (1000) | Direct | |
| 2024-03-13 | Tranche B Warrant | $ | P | 1000 | Acquired | Common Stock (1000) | Direct |
Footnotes
F1: The exercise price of the Tranche A Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
F2: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
F3: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
F4: The exercise price of the Tranche B Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
F5: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
F6: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.